4 - {[4 - ({[4- (2,2,2-trifluoroethoxy) -1,2-benzisoxazol-3-yl] oxy} methyl) piperidin-1-yl] methyl} -tetrahydroic acid polymorphic form 2h-pyran-4-carboxylic acid, 4 - {[4 - ({[4- (2,2,2-trifluoroethoxy) -1,2-benzisoxazol-3-yl] oxy} methyl) piperidine acid 1-yl] methyl} -tetrahydro-2h-pyran-4 carboxylic acid, use and process, and method for treating disease conditions mediated by 5-ht4 receptor activity

• 收藏
• 分享

专利权人:

RAQUALIA PHARMA INC.

发明人:

HIROHIDE NOGUCHI,NOBUAKI WAIZUMI,TAKASHI KOJIMA,TOYOHARU NUMATA

申请号：

BR112013029319

公开号：

BR112013029319A2

申请日:

2012.05.18

申请国别(地区):

BR

年份:

2017

代理人:

摘要：

The present invention relates to novel crystal forms of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid. More particularly, the invention relates to polymorph forms (Polymorph Form I or Polymorph Form II), and to processes for the preparation of, compositions containing and to uses of, such polymorph forms.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/